Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized placebo-controlled study of MEDI6012 in acute ST-elevation myocardial infarction
NL-OMON48930Phase 2Completed
- Sponsor
- MedImmune
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human lecithin-cholesterol acyltransferase in myocardial infarction (MI) (4 cohorts), sponsored by MedImmune. Primary endpoint: Infarct size. Started Oct 2018; status: completed.
02
Drugs
recombinant human lecithin-cholesterol acyltransferase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON48930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48930.